Form 4: Integra LifeSciences Director Stuart Essig Adjusts Share Holdings

Integra LifeSciences Director Stuart Essig reported changes in his beneficial ownership, including transfers to a grantor trust and distributions from grantor retained annuity trusts.

Summary

• Stuart Essig, a Director of Integra LifeSciences Holdings Corp (IART), reported changes in his beneficial ownership of common stock.
• On August 14, 2025, Essig transferred 200,000 shares of common stock at a price of $13.62 per share to a grantor trust, for which his spouse is the trustee.
• This transfer resulted in a decrease of 200,000 shares in his direct beneficial ownership and a corresponding increase of 200,000 shares in his indirect beneficial ownership through the grantor trust.
• In exchange for the shares, the trust transferred assets with a fair market value equal to the transferred shares to Essig.
• On August 8, 2025, Essig received 180,080 shares of common stock as an annuity payment from a grantor retained annuity trust (GRAT E).
• Also on August 8, 2025, Essig received 500,000 shares of common stock as an annuity payment from another grantor retained annuity trust (GRAT F).
• GRAT F was terminated following this distribution as the available shares were insufficient to satisfy the full annuity payment obligation.
• Following these transactions, Essig's beneficial ownership stands at 1,152,236 shares directly, 219,920 shares indirectly via GRAT E, 0 shares indirectly via GRAT F, 213,115 shares indirectly via a Family Trust, and 200,000 shares indirectly via the new Grantor Trust.

Sentiment

Score: 5

Explanation: The filing is a standard Form 4 reporting insider transactions related to estate planning and pre-arranged trust distributions, which do not inherently indicate positive or negative sentiment regarding the company's operational performance or future prospects.

Future Outlook

NA

Industry Context

This filing is a standard insider transaction report (Form 4) and does not provide information directly related to broader industry trends or competitive landscape within the medical technology or life sciences sector.

Related Party Transactions

• Transfer of 200,000 shares of common stock to a grantor trust for which the reporting person's spouse is the trustee.
• Distribution of shares from Grantor Retained Annuity Trusts (GRAT E and GRAT F) to the reporting person.

Stakeholder Impact

• Minimal direct impact on external shareholders as these transactions primarily represent internal adjustments to a director's beneficial ownership structure, often for estate planning purposes, rather than open market sales or purchases that signal a change in company valuation or operational outlook.

Key Dates

Recommendation

The Form 4 filing details pre-arranged insider transactions, specifically transfers to grantor trusts and distributions from grantor retained annuity trusts (GRATs). These are typically estate planning activities and do not reflect a change in the company's operational performance, financial health, or strategic direction. As such, they do not provide new information that would warrant a change in an existing investment recommendation.

Keywords

Integra LifeSciences, IART, SEC Form 4, Insider Transaction, Beneficial Ownership, Stuart Essig, Director, Grantor Trust, GRAT, Equity Transfer